HPV Vaccines
The Human Papillomavirus (HPV) is the most common viral infection of the reproductive tract and a major cause of cervical cancer, genital warts, and several other cancers affecting both women and men.
Vaccination is the most effective way to prevent HPV infection and its complications.
Affinity Vaccines provides safe and effective HPV vaccination programs using Cervarix®, Gardasil®, and Gardasil® 9—globally trusted vaccines approved by the World Health Organization (WHO) and the Philippine Food and Drug Administration (FDA).
All HPV vaccines are administered by licensed healthcare professionals under strict cold-chain compliance, suitable for corporate immunization programs, women’s health initiatives, and dependent vaccination drives.
A. Bivalent HPV Vaccine
1. Cervarix® (GlaxoSmithKline – GSK)
Formulation:
Bivalent Human Papillomavirus Vaccine (Types 16 and 18, recombinant, AS04-adjuvanted).
Packaging:
0.5 mL single-dose pre-filled syringe.
Dosage and Administration:
- Ages 9–14 years: Two doses (0 and 6 months).
- Ages 15 years and older: Three doses (0, 1, and 6 months).
- Administer via intramuscular injection in the deltoid region.
Indications:
Active immunization against oncogenic HPV types 16 and 18, responsible for approximately 70% of cervical cancers and other anogenital malignancies.
Contraindications:
- Known hypersensitivity to any component of the vaccine, including AS04 adjuvant or yeast proteins.
- Defer vaccination during moderate or severe acute illness.
- Not indicated for treatment of existing HPV infection or lesions.
Storage / Cold-Chain Requirement:
- Store at +2°C to +8°C.
- Do not freeze. Discard if frozen.
- Protect from light.
Manufacturer:
GlaxoSmithKline Biologicals S.A., Belgium
B. Quadrivalent HPV Vaccine
2. Gardasil® (Merck Sharp & Dohme – MSD)
Formulation:
Quadrivalent Human Papillomavirus Vaccine (Types 6, 11, 16, 18, recombinant).
Packaging:
0.5 mL single-dose pre-filled syringe or vial.
Dosage and Administration:
- Ages 9–14 years: Two doses (0 and 6–12 months).
- Ages 15–45 years: Three doses (0, 2, and 6 months).
- Intramuscular injection in the deltoid area.
Indications:
Prevention of diseases caused by HPV types 6, 11, 16, and 18, including:
- Cervical, vulvar, and vaginal cancers
- Genital warts (condyloma acuminata)
- Precancerous cervical and anal lesions
Contraindications:
- Hypersensitivity to any component, including yeast or amorphous aluminum hydroxyphosphate sulfate.
- Postpone vaccination during moderate or severe illness.
Storage / Cold-Chain Requirement:
- Store between +2°C and +8°C.
- Do not freeze.
- Protect from light.
Manufacturer:
Merck Sharp & Dohme Corp., USA
C. 9-Valent HPV Vaccine
3. Gardasil® 9 (Merck Sharp & Dohme – MSD)
Formulation:
9-Valent Human Papillomavirus Vaccine (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58, recombinant).
Packaging:
0.5 mL pre-filled syringe or vial, single-dose.
Dosage and Administration:
- Ages 9–14 years: Two doses (0 and 6–12 months).
- Ages 15–45 years: Three doses (0, 2, and 6 months).
- Intramuscular injection in the deltoid region.
Indications:
Active immunization against HPV types 6, 11, 16, 18, 31, 33, 45, 52, and 58, covering about 90% of HPV-related cervical cancers and the majority of genital warts.
Provides broader protection than earlier bivalent and quadrivalent vaccines.
Contraindications:
- Hypersensitivity to yeast or any vaccine component.
- Delay vaccination if febrile or acutely ill.
- Not a treatment for existing HPV infection or lesions.
Storage / Cold-Chain Requirement:
- Store at +2°C to +8°C.
- Do not freeze.
- Protect from light.
Manufacturer:
Merck Sharp & Dohme Corp., USA
HPV Vaccine Selection and Recommendations
Target Group | Recommended Vaccine(s) | Notes |
Females 9–26 years | Gardasil 9 / Cervarix | Highest protection against cervical cancer. |
Males 9–26 years | Gardasil 9 / Gardasil | Prevents genital warts and anal cancers. |
Adults 27–45 years | Gardasil 9 (medical discretion) | Protection for sexually active adults. |
Corporate dependents (spouses, teens) | Gardasil 9 / Cervarix | Ideal for inclusion in dependent programs. |
Affinity Vaccines Recommendation:
For broad, long-term protection of both men and women, Gardasil 9 is the preferred vaccine due to its coverage of nine HPV types associated with cancer and genital warts.
Cold-Chain and Safety Assurance
All HPV vaccines are stored and transported under strict cold-chain monitoring (2 °C – 8 °C) and administered only by licensed medical professionals.
Post-vaccination observation and documentation are standard protocol for every corporate vaccination campaign.
Protect Your People. Protect Your Business. Strengthen Your Organization.
HPV-related cancers are largely preventable through vaccination.
Affinity Vaccines offers corporate HPV vaccination programs to protect employees and dependents from cervical cancer, genital warts, and other HPV-related diseases.
Our Corporate Program Management Team manages planning, scheduling, and safe on-site vaccination using Cervarix®, Gardasil®, and Gardasil 9.
📩 Request for a Corporate Vaccination Proposal
Email: vaccines@affinity.com.ph